On several occasions each year, Industry Standard Research (ISR) has the opportunity to speak with sponsor companies about their outsourcing practices.
On several occasions each year, Industry Standard Research (ISR) has the opportunity to speak with sponsor companies about their outsourcing practices. One common topic is CRO selection. Almost invariably sponsors tell us that Therapeutic Expertise is the single most important criterion for selecting a partner for clinical research. In a recent study, however, we also decided to ask which attributes were becoming more important in their selection of service providers.
ISR's data show that not only is Therapeutic Expertise important in today's environment, it is becoming increasingly so; and if our sample is any indication, Oncology and CNS are the areas of focus.
Requirements Evolve for Service Providers
But here's the real news—and the challenge for CROs—sponsors indicate that they want this additional expertise at lower costs. Alongside Therapeutic Expertise, Low Cost is expected to surge as a significant driver of CRO selection. This finding is new in our research. Historically, low cost has shown up 4th or 5th among selection drivers behind characteristics such as Project Manager Quality and Project Team Chemistry, but this appears to be changing.
As sponsors sharpen their pencils, the pressure will increase on CROs to demonstrate value like never before.—Industry Standard Research, www.ISRreports.com
Industry Assessment of Risk-Based Quality Management Emphasizes Value of Adoption
April 4th 2024A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.